NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/22/2024
Back to search
Official data from USPTO
HOPA ORAL CHEMOTHERAPY COLLABORATIVE (OCC)
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
HOPA ORAL CHEMOTHERAPY COLLABORATIVE (OCC)
ST13
US500000097481520Class
35
Filing
97481520
Registration
7545435
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
10/22/2024
Trademark type
Word
Nice classes
35
Filing date
06/29/2022
Registration date
10/22/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/22/2024
Last transaction
10/22/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
08/09/2021
First use in commerce
08/09/2021
Drawing code
4
Owner type
99
Owner location
Milwaukee, WI, US
Examiner
KEATING, MICHAEL P
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Hematology/Oncology Pharmacy Association, Inc.
Representatives
Melissa A. Vallone BARNES & THORNBURG LLP
Technical classification
Nice Classes
Class 35
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
association servicespromoting the interests of pharmacy practitioners in the area of hematology/oncology to achieve advances in the optimization of care of individuals taking oral anticancer agents for cancer treatment
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
10/22/2024
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
02/16/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/13/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/12/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/10/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/10/2024
IUAF
USE AMENDMENT FILED
01/22/2024
EISU
TEAS STATEMENT OF USE RECEIVED
01/22/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/08/2023
PUBO
PUBLISHED FOR OPPOSITION
08/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/19/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/30/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/30/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/30/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/17/2023
GNRT
NON-FINAL ACTION E-MAILED
04/17/2023
CNRT
NON-FINAL ACTION WRITTEN
04/17/2023
DOCK
ASSIGNED TO EXAMINER
04/13/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/19/2022
NWAP
NEW APPLICATION ENTERED
07/02/2022
Continuous trademark protection
Get notified about every new filing that threatens HOPA ORAL CHEMOTHERAPY COLLABORATIVE (OCC) or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.